Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis
- PMID: 23376359
- DOI: 10.1016/j.jhep.2013.01.024
Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis
Comment in
-
Reply to: "usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis".J Hepatol. 2013 Jun;58(6):1260. doi: 10.1016/j.jhep.2013.01.027. Epub 2013 Jan 29. J Hepatol. 2013. PMID: 23376364 No abstract available.
Comment on
-
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.J Hepatol. 2013 Mar;58(3):488-94. doi: 10.1016/j.jhep.2012.11.013. Epub 2012 Nov 23. J Hepatol. 2013. PMID: 23183521 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
